Claudin18.2 binding moieties and uses thereof

Patent metadata

Field	Value
Publication number	US-12258418-B2
Application number	US-201917419203-A
Country	US
Kind code	B2
Filing date	Dec 27, 2019
Priority date	Dec 28, 2018
Publication date	Mar 25, 2025
Grant date	Mar 25, 2025

Abstract

Described herein are binding moieties, such as antibodies, that specifically bind Claudin18.2, and chimeric antigen receptors comprising such binding moieties. Further provided are engineered immune cells (such as T cells) comprising anti-Claudin 18.2 chimeric antigen receptors. Also disclosed are methods of treating Claudin18.2-expressing tumor or cancers using the binding moieties, chimeric antigen receptors and engineered immune cells.

First claim

What is claimed is:

1. A binding moiety that specifically binds to Claudin18.2, comprising:
(1) VH CDR1, VH CDR2, and VH CDR3, comprising the amino acid sequences of SEQ ID NOs: 77, 102, and 124, respectively; and VL CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 141, 148, and 161, respectively;
(2) VH CDR1, VH CDR2, and VH CDR3, comprising the amino acid sequences of SEQ ID NOs: 78, 103, and 125, respectively; and VL CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 136, 143, and 162, respectively;
(3) VH CDR1, VH CDR2, and VH CDR3, comprising the amino acid sequences of SEQ ID NOs: 79, 104, and 126, respectively; and VL CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 136, 149, and 163, respectively;
(4) VH CDR1, VH CDR2, and VH CDR3, comprising the amino acid sequences of SEQ ID NOs: 78, 105, and 127, respectively; and VL CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 142, 143, and 164, respectively; or
(5) VH CDR1, VH CDR2, and VH CDR3, comprising the amino acid sequences of SEQ ID NOs: 209, 103 and 125, respectively; and VL CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 136, 143, and 162, respectively.

2. The binding moiety of claim 1 , wherein the VH and the VL comprise
(1) the amino acid sequences of SEQ ID NOs: 37 and 38, respectively;
(2) the amino acid sequence of any one of SEQ ID NOs: 372-374 and the amino acid sequence of any one of SEQ ID NOs: 375-377, respectively;
(3) the amino acid sequences of SEQ ID NOs: 39 and 40, respectively;
(4) the amino acid sequences of SEQ ID NOs: 41 and 42, respectively;
(5) the amino acid sequences of SEQ ID NOs: 43 and 44, respectively;
(6) the amino acid sequence of any one of SEQ ID NOs: 355-362 and the amino acid sequence of either of SEQ ID NOs: 363 and 364, respectively;
(7) the amino acid sequences of SEQ ID NOs: 521 and 522, respectively;
(8) the amino acid sequences of SEQ ID NOs: 523 and 524, respectively; or
(9) the amino acid sequences of SEQ ID NOs: 525 and 526, respectively.

3. The binding moiety of claim 1 , which is a Fab, a Fab′, a F (ab′) 2 , a Fv, a scFv, a (scFv) 2 , or a full-length antibody.

4. The binding moiety of claim 1 , which is a mouse, chimeric, humanized or human binding moiety.

5. A pharmaceutical composition comprising a therapeutically effective amount of the binding moiety of claim 1 , and a pharmaceutically acceptable carrier.

6. A chimeric antigen receptor comprising:
(a) an extracellular antigen binding domain comprising the binding moiety of claim 1 , wherein the binding moiety is a single chain variable fragment (scFv);
(b) a transmembrane domain; and
(c) an intracellular signaling domain.

7. The chimeric antigen receptor of claim 6 , comprising an amino acid sequence having at least 80%, 85%, 90%, 95% or 99% sequence identity to SEQ ID NO: 314, 315, or 304.

8. The chimeric antigen receptor of claim 7 , comprising SEQ ID NO: 314, 315, or 304.

9. A nucleic acid encoding the chimeric antigen receptor of claim 6 .

10. An engineered immune cell comprising the nucleic acid of claim 9 .

11. The engineered immune cell of claim 10 , wherein the engineered immune cell is a T cell.

12. A pharmaceutical composition comprising a therapeutically effective amount of the engineered immune cell of claim 10 , and a pharmaceutically acceptable carrier.

13. A method of treating a Claudin18.2-expressing tumor or cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the engineered immune cell of claim 10 .

14. A pharmaceutical composition comprising a therapeutically effective amount of the chimeric antigen receptor of claim 6 , and a pharmaceutically acceptable carrier.

15. A nucleic acid encoding the binding moiety of claim 1 .

16. An expression vector comprising the nucleic acid of claim 15 and a regulatory element.

17. A host cell comprising the expression vector of claim 16 .

18. A cell comprising the binding moiety of claim 1 .

19. A method of treating a Claudin18.2-expressing tumor or cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the binding moiety of claim 1 .

20. The method of claim 19 , wherein the Claudin18.2-expressing tumor or cancer is gastric, esophageal, gastroesophageal, pancreatic, ovarian, or lung tumor or cancer.

Assignees

• Nanjing Genscript Biotech Co Ltd
• Nanjing Legend Biotech Co Ltd

Inventors

• Yin Liusong
• Zhou Tielin
• Fang Zhuo
• Liu Yong
• Zhuang Qiuchuan
• Wu Bo
• Fan Xiaohu
• Zhang Qingshan
• Zhao Dan
• Mao Jie

Classifications

• C07K2319/33

  fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title

• C07K2319/03

  containing a transmembrane segment · CPC title

• C07K2319/02

  containing a signal sequence · CPC title

• C07K2317/734

  Complement-dependent cytotoxicity [CDC] · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title